COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a global health crisis.
• The lack of specific antiviral therapies necessitates urgent development of effective treatments.
• Existing small molecule drugs and experimental compounds are being investigated for potential therapeutic use.

Purpose of the Study:

• To evaluate fourteen selected small molecule drugs for their potential against SARS-CoV-2.
• To assess the bioavailability and physicochemical properties of these candidate drugs.
• To identify patterns and characteristics beneficial for antiviral drug optimization and new agent design.

Main Methods:

• Expert selection of fourteen existing or experimental small molecule drugs.
• Application of Lipinski’s Rule of Five and Veber’s rules for bioavailability assessment.
• Analysis of physicochemical descriptors to understand drug properties.

Main Results:

• Physicochemical descriptors and bioavailability were evaluated for selected drugs.
• Potential similarities and unique characteristics relevant to antiviral activity were identified.
• The study provides a basis for further drug optimization and development.

Conclusions:

• The evaluation of physicochemical properties and bioavailability is crucial for identifying potential SARS-CoV-2 therapeutics.
• Findings can inform the design of novel antiviral agents and optimized drug combinations.
• This research contributes to the urgent need for effective treatments against COVID-19.